Supplement Peer
Peer-reviewed supplements
Analyze/NMN 500
Nicotinamide mononucleotide (NMN), 500 mg capsule
Sample analysis

It reliably raises blood NAD+, a surrogate marker, but a decade of human trials shows no consistent clinical or longevity payoff.

Replace NMN 500 with creatine monohydrate.

REPLACE
Better alternative exists
TIER D EVIDENCE €1.67 / DAY
Evidence
Tier D
Hopium
Dose
500 mg once nightly
Meets studied range
Interactions
1
See screening below
Cost / day
€1.67
Per effective dose
Hype vs. evidence
The label's claims, rewritten honestly against what human trials actually show.
Claim
“Activates sirtuins and slows aging”
Evidence
No human trial has shown a longevity or anti-aging clinical outcome; sirtuin activation is a mechanism, not a result.
Claim
“Raises your NAD+ levels”
Evidence
True and dose-dependent, but NAD+ is a surrogate marker that has not tracked any clinical benefit.
Claim
“Boosts energy and athletic performance”
Evidence
A placebo-controlled study at 1000 mg/day found no change in strength, aerobic capacity, or insulin sensitivity vs. placebo.
Claim
“Improves insulin sensitivity”
Evidence
One 250 mg trial in prediabetic women moved a clamp measure, but weight, blood pressure, and lipids didn't budge, and it hasn't consistently replicated.
The evidence
ABCDF
Hopium

Human NMN trials consistently move a biomarker (blood NAD+) but not the clinical outcomes that would justify the price. In postmenopausal prediabetic women, 250 mg/day for 10 weeks raised skeletal-muscle insulin sensitivity on a hyperinsulinemic-euglycemic clamp, yet body weight, blood pressure and lipids did not change [1]. In amateur runners, 300–1200 mg/day for 6 weeks nudged ventilatory-threshold aerobic capacity but left peak VO2 (VO2max) unchanged [2]. Pharmaceutical-grade beta-NMN raises circulating NAD+ in a clear dose-dependent way [3], but a placebo-controlled physiologic study at 1000 mg/day found NAD+ rose while muscle strength, aerobic capacity and insulin sensitivity did not differ from placebo [4], and 250 mg/day for 24 weeks in older diabetic men failed to improve grip strength or walking speed [5]. NMN is well tolerated up to 1250 mg/day with no serious adverse events [6], and a 2025 meta-analysis of 9 RCTs (412 participants) found only small effects on gait speed (SMD ~0.34) and liver enzymes, with no anti-aging clinical endpoint met [7]. A biomarker that merely tracks a disease is not proof that changing it changes outcomes, the central lesson of surrogate-endpoint failures [8], so a higher NAD+ level is a surrogate, not a demonstrated longevity benefit. For the same money, creatine monohydrate delivers replicated ergogenic effects [9] and measurable memory and processing-speed gains (memory SMD ~0.29–0.31), strongest in older adults [10].

Quality audit
Trust score
Amber
GMP verified
Registry-confirmed
Third-party tested
No independent testing
Certificate of Analysis
Batch-generic certificate of analysis typical for the category; lot-specific third-party COA usually absent
Contaminant risk
NMN identity, purity and heavy-metal screening rarely independently verified; NMN also degrades with heat/humidity, so label mg is not proof of delivered mg
Transparency
Label states 500 mg NMN, but sourcing, polymorph/identity testing and stability data are seldom disclosed, as is typical of the longevity-supplement category
Interaction screening
NMN + other NAD+ precursors (nicotinamide riboside, niacin, nicotinamide)
No clinically significant drug interactions are established for NMN. Stacking it with other NAD+ precursors is redundant rather than dangerous; you pay for overlapping pathways without added proven benefit.
Minor
CriticalSignificantMinorBeneficial
Cost per effective dose
€1.67/ day · per effective dose
Category benchmark · €0.10
≈17× the category benchmark for the same outcome.
What you’re actually paying for
€50.00 / month
Active NMN compound · 30%Brand & 'longevity' premium · 50%Capsules & packaging · 20%
Before you buy
What to verify before buying
  • A lot-specific third-party Certificate of Analysis (identity + purity), not a generic batch cert
  • β-NMN identity and heavy-metal screening from a named lab
  • Stability / storage guidance: NMN degrades with heat and humidity, so label mg ≠ delivered mg
Why this verdict could change
  • A large RCT demonstrates a hard clinical or functional endpoint, not just a higher NAD+ level
  • Long-term outcome data emerges at a realistic, affordable dose
  • Price falls to within ~2× of creatine per proven effective outcome
Cited references · 10 key sources
[1]Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. PMID: 33888596. DOI: 10.1126/science.abe9985 (250 mg/day for 10 weeks; clamp-measured insulin sensitivity up, but body weight, blood pressure and lipids unchanged).
[2]Liao B, Zhao Y, Wang D, et al. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. J Int Soc Sports Nutr. 2021;18(1):54. PMID: 34238308. DOI: 10.1186/s12970-021-00442-4 (300/600/1200 mg/day, 6 weeks; ventilatory-threshold gains but no change in peak VO2).
[3]Pencina KM, Lavu S, Dos Santos M, et al. MIB-626, an oral formulation of a microcrystalline unique polymorph of beta-nicotinamide mononucleotide, increases circulating NAD and its metabolome in middle-aged and older adults. J Gerontol A Biol Sci Med Sci. 2023;78(1):90-96. PMID: 35182418. DOI: 10.1093/gerona/glac049 (dose-dependent rise in blood NAD+, a surrogate pharmacodynamic marker).
[4]Pencina KM, Valderrabano R, Wipper B, et al. Nicotinamide adenine dinucleotide augmentation in overweight or obese middle-aged and older adults: a physiologic study. J Clin Endocrinol Metab. 2023;108(8):1968-1980. PMID: 36740954. DOI: 10.1210/clinem/dgad027 (NAD+ rose, but muscle strength, aerobic capacity and insulin sensitivity did not differ from placebo).
[5]Akasaka H, Nakagami H, Sugimoto K, et al. Effects of nicotinamide mononucleotide on older patients with diabetes and impaired physical performance: a prospective, placebo-controlled, double-blind study. Geriatr Gerontol Int. 2023;23(1):38-43. PMID: 36443648. DOI: 10.1111/ggi.14513 (250 mg/day, 24 weeks; no improvement in grip strength or walking speed).
[6]Fukamizu Y, Uchida Y, Shigekawa A, et al. Safety evaluation of beta-nicotinamide mononucleotide oral administration in healthy adult men and women. Sci Rep. 2022;12(1):14442. PMID: 36002548. DOI: 10.1038/s41598-022-18272-y (1250 mg/day for 4 weeks well tolerated, no serious adverse events).
[7]Wang JP, Wang L, Wang T, et al. Effects of nicotinamide mononucleotide supplementation on muscle and liver functions among the middle-aged and elderly: a systematic review and meta-analysis of randomized controlled trials. Curr Pharm Biotechnol. 2025;26(13):2141-2152. PMID: 39185644. DOI: 10.2174/0113892010306242240808094303 (9 RCTs, 412 participants; small effects on gait speed and ALT, no anti-aging clinical endpoint met).
[8]Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125(7):605-613. PMID: 8815760 (foundational statement that a biomarker responding to treatment does not establish clinical benefit).
[9]Kreider RB, Kalman DS, Antonio J, et al. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. J Int Soc Sports Nutr. 2017;14:18. PMID: 28615996. DOI: 10.1186/s12970-017-0173-z (replicated ergogenic benefit; safe up to 30 g/day short-term and ~3–5 g/day long-term).
[10]Prokopidis K, Giannos P, Triantafyllidis KK, et al. Effects of creatine supplementation on memory in healthy individuals: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev. 2023;81(4):416-427. PMID: 35984306. DOI: 10.1093/nutrit/nuac064 (memory SMD 0.29, 95% CI 0.04–0.53; largest effect in adults aged 66–76).